In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

In September 2024, Pfizer voluntarily withdrew large amounts of the sickle cell disease treatment medication Voxelotor, sold under the brand name Oxbryta, from worldwide markets. However ...

As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

Oxbryta is manufactured as an oral therapy for patients with sickle cell disease. Hardiman began taking Oxbryta in 2020 under the belief that it would help manage his sickle cell disease.

This electron microscope image provided by the National Institutes of Health in 2016 shows a blood cell altered by sickle cell disease, top. (National Center for Advancing Translational Sciences ...

Sickle cell disease (SCD) is a group of genetic blood disorders. A person inherits SCD from their parents when they inherit two copies of the sickle cell gene, one from each parent. This ...

The email explained that Pfizer, which manufactured and sold voxelotor under the brand name Oxbryta ... way forward for people living with sickle cell disease, and to increase awareness among ...

A new study finds that preschool-aged children with sickle cell disease (SCD) who live in food deserts and have limited access to transportation are at greater risk for acute complications and ...